Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Total Current Liabilities (2021 - 2025)

Kiniksa Pharmaceuticals International (KNSA) has disclosed Total Current Liabilities for 5 consecutive years, with $139.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Total Current Liabilities rose 38.33% year-over-year to $139.2 million, compared with a TTM value of $139.2 million through Dec 2025, up 38.33%, and an annual FY2025 reading of $139.2 million, up 38.33% over the prior year.
  • Total Current Liabilities was $139.2 million for Q4 2025 at Kiniksa Pharmaceuticals International, up from $123.6 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $139.2 million in Q4 2025 and bottomed at $34.4 million in Q3 2021.
  • Average Total Current Liabilities over 5 years is $68.8 million, with a median of $55.0 million recorded in 2022.
  • The sharpest move saw Total Current Liabilities fell 27.34% in 2023, then soared 79.46% in 2024.
  • Year by year, Total Current Liabilities stood at $44.8 million in 2021, then grew by 5.0% to $47.1 million in 2022, then surged by 35.27% to $63.7 million in 2023, then skyrocketed by 58.05% to $100.6 million in 2024, then skyrocketed by 38.33% to $139.2 million in 2025.
  • Business Quant data shows Total Current Liabilities for KNSA at $139.2 million in Q4 2025, $123.6 million in Q3 2025, and $117.8 million in Q2 2025.